Which has better earnings and valuation, TARA or FLNA?

Protara Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Protara Therapeutics N/A N/A -$57.44M -$1.34 N/A Cassava Sciences N/A N/A -$90.97M -$1.61 N/A

Is TARA or FLNA more profitable?

Protara Therapeutics' return on equity of -38.70% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Protara Therapeutics N/A -38.70% -36.02% Cassava Sciences N/A -53.90% -34.20%

Cassava Sciences (FLNA) Competitors

$1.23 0.00 (0.00%)

As of 07/2/2026 04:00 PM Eastern

Compare

FLNA vs. TARA, RNA, CHRS, KPTI, and VYGR

Should you buy Cassava Sciences stock or one of its competitors? MarketBeat compares Cassava Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cassava Sciences include Protara Therapeutics (TARA), Avidity Biosciences (RNA), Coherus Oncology (CHRS), Karyopharm Therapeutics (KPTI), and Voyager Therapeutics (VYGR). These companies are all part of the "pharmaceutical products" industry.

How does Cassava Sciences compare to Protara Therapeutics?

Protara Therapeutics (NASDAQ:TARA) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Protara Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.73, indicating that its stock price is 173% less volatile than the broader market.

In the previous week, Protara Therapeutics had 2 more articles in the media than Cassava Sciences. MarketBeat recorded 2 mentions for Protara Therapeutics and 0 mentions for Cassava Sciences. Protara Therapeutics' average media sentiment score of 0.00 equaled Cassava Sciences'average media sentiment score.

Company	Overall Sentiment
Protara Therapeutics	Neutral
Cassava Sciences	Neutral

Protara Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.34	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

Protara Therapeutics' return on equity of -38.70% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protara Therapeutics	N/A	-38.70%	-36.02%
Cassava Sciences	N/A	-53.90%	-34.20%

Protara Therapeutics presently has a consensus target price of $26.25, indicating a potential upside of 546.55%. Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 306.50%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Protara Therapeutics is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 7.6% of Protara Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Protara Therapeutics beats Cassava Sciences on 10 of the 12 factors compared between the two stocks.

How does Cassava Sciences compare to Avidity Biosciences?

Cassava Sciences (NASDAQ:FLNA) and Avidity Biosciences (NASDAQ:RNA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

In the previous week, Cassava Sciences' average media sentiment score of 0.00 equaled Avidity Biosciences'average media sentiment score.

Company	Overall Sentiment
Cassava Sciences	Neutral
Avidity Biosciences	Neutral

Cassava Sciences has higher earnings, but lower revenue than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
Avidity Biosciences	$36.68M	6.37	-$322.30M	-$0.97	N/A

Cassava Sciences has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. Avidity Biosciences' return on equity of -44.92% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%

Cassava Sciences has a beta of -0.73, suggesting that its share price is 173% less volatile than the broader market. Comparatively, Avidity Biosciences has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

38.1% of Cassava Sciences shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by insiders. Comparatively, 3.8% of Avidity Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cassava Sciences currently has a consensus price target of $5.00, indicating a potential upside of 306.50%. Avidity Biosciences has a consensus price target of $66.81, indicating a potential upside of 389.47%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.32

Summary

Avidity Biosciences beats Cassava Sciences on 8 of the 14 factors compared between the two stocks.

How does Cassava Sciences compare to Coherus Oncology?

Coherus Oncology (NASDAQ:CHRS) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Coherus Oncology presently has a consensus target price of $8.67, indicating a potential upside of 497.70%. Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 306.50%. Given Coherus Oncology's stronger consensus rating and higher possible upside, equities research analysts clearly believe Coherus Oncology is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Coherus Oncology has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.30	$168.02M	$1.67	0.87
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

Coherus Oncology has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.73, suggesting that its stock price is 173% less volatile than the broader market.

In the previous week, Coherus Oncology's average media sentiment score of 0.00 equaled Cassava Sciences'average media sentiment score.

Company	Overall Sentiment
Coherus Oncology	Neutral
Cassava Sciences	Neutral

72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 8.1% of Coherus Oncology shares are held by company insiders. Comparatively, 4.6% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Coherus Oncology has a net margin of 397.30% compared to Cassava Sciences' net margin of 0.00%. Cassava Sciences' return on equity of -53.90% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
Cassava Sciences	N/A	-53.90%	-34.20%

Summary

Coherus Oncology beats Cassava Sciences on 11 of the 13 factors compared between the two stocks.

How does Cassava Sciences compare to Karyopharm Therapeutics?

Cassava Sciences (NASDAQ:FLNA) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Cassava Sciences has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Cassava Sciences has a beta of -0.73, meaning that its share price is 173% less volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Cassava Sciences currently has a consensus price target of $5.00, indicating a potential upside of 306.50%. Karyopharm Therapeutics has a consensus price target of $17.17, indicating a potential upside of 78.82%. Given Cassava Sciences' higher probable upside, equities research analysts plainly believe Cassava Sciences is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Cassava Sciences has higher earnings, but lower revenue than Karyopharm Therapeutics. Cassava Sciences is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
Karyopharm Therapeutics	$151.12M	1.44	-$196.04M	-$15.09	N/A

In the previous week, Karyopharm Therapeutics had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 1 mentions for Karyopharm Therapeutics and 0 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.00 equaled Karyopharm Therapeutics'average media sentiment score.

Company	Overall Sentiment
Cassava Sciences	Neutral
Karyopharm Therapeutics	Neutral

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Karyopharm Therapeutics beats Cassava Sciences on 9 of the 15 factors compared between the two stocks.

How does Cassava Sciences compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Voyager Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 336.51%. Cassava Sciences has a consensus price target of $5.00, indicating a potential upside of 306.50%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Voyager Therapeutics had 4 more articles in the media than Cassava Sciences. MarketBeat recorded 4 mentions for Voyager Therapeutics and 0 mentions for Cassava Sciences. Voyager Therapeutics' average media sentiment score of 0.45 beat Cassava Sciences' score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Voyager Therapeutics	Neutral
Cassava Sciences	Neutral

Cassava Sciences has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -319.61%. Cassava Sciences' return on equity of -53.90% beat Voyager Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-319.61%	-55.97%	-43.12%
Cassava Sciences	N/A	-53.90%	-34.20%

Cassava Sciences has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$36.49M	6.26	-$119.72M	-$1.97	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

Voyager Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.73, suggesting that its stock price is 173% less volatile than the broader market.

48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Voyager Therapeutics beats Cassava Sciences on 10 of the 16 factors compared between the two stocks.

Get Cassava Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLNA vs. The Competition

Export

Metric	Cassava Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$59.42M	$3.10B	$7.17B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	-0.76	20.06	28.02	24.70
Price / Sales	N/A	360.33	540.72	98.05
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	0.80	4.32	10.96	6.46
Net Income	-$90.97M	$64.45M	$3.57B	$337.01M
7 Day Performance	2.50%	2.97%	2.12%	1.69%
1 Month Performance	-6.82%	6.83%	5.25%	3.81%
1 Year Performance	-38.81%	29.07%	33.29%	23.90%

Cassava Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLNA Cassava Sciences	1.5774 of 5 stars	$1.23 flat	$5.00 +306.5%	-38.8%	$59.42M	N/A	N/A	20
TARA Protara Therapeutics	3.0827 of 5 stars	$4.09 -0.8%	$26.25 +542.6%	+39.7%	$229.58M	N/A	N/A	30	Gap Down
RNA Avidity Biosciences	1.9465 of 5 stars	$13.29 +0.8%	$66.81 +402.7%	-53.1%	$227.34M	$36.68M	N/A	190
CHRS Coherus Oncology	3.0467 of 5 stars	$1.46 -3.0%	$8.67 +495.6%	+81.0%	$225.98M	$42.17M	0.88	330
KPTI Karyopharm Therapeutics	1.5539 of 5 stars	$9.80 -4.1%	$17.17 +75.3%	+107.8%	$222.23M	$151.12M	N/A	380

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLNA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cassava Sciences (FLNA) Competitors

FLNA vs. TARA, RNA, CHRS, KPTI, and VYGR

How does Cassava Sciences compare to Protara Therapeutics?

Summary

How does Cassava Sciences compare to Avidity Biosciences?

Summary

How does Cassava Sciences compare to Coherus Oncology?

Summary

How does Cassava Sciences compare to Karyopharm Therapeutics?

Summary

How does Cassava Sciences compare to Voyager Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cassava Sciences (FLNA) Competitors

FLNA vs. TARA, RNA, CHRS, KPTI, and VYGR

How does Cassava Sciences compare to Protara Therapeutics?

Which has more volatility & risk, TARA or FLNA?

Does the media favor TARA or FLNA?

Which has better earnings and valuation, TARA or FLNA?

Is TARA or FLNA more profitable?

Do analysts prefer TARA or FLNA?

Do institutionals & insiders believe in TARA or FLNA?

Summary

How does Cassava Sciences compare to Avidity Biosciences?

Does the media favor FLNA or RNA?

Which has higher valuation & earnings, FLNA or RNA?

Is FLNA or RNA more profitable?

Which has more risk & volatility, FLNA or RNA?

Do institutionals and insiders hold more shares of FLNA or RNA?

Do analysts recommend FLNA or RNA?

Summary

How does Cassava Sciences compare to Coherus Oncology?

Do analysts recommend CHRS or FLNA?

Which has preferable earnings and valuation, CHRS or FLNA?

Which has more risk and volatility, CHRS or FLNA?

Does the media favor CHRS or FLNA?

Do institutionals & insiders believe in CHRS or FLNA?

Is CHRS or FLNA more profitable?

Summary

How does Cassava Sciences compare to Karyopharm Therapeutics?

Is FLNA or KPTI more profitable?

Which has more risk & volatility, FLNA or KPTI?

Do analysts rate FLNA or KPTI?

Which has higher earnings and valuation, FLNA or KPTI?

Does the media prefer FLNA or KPTI?

Do insiders & institutionals have more ownership in FLNA or KPTI?

Summary

How does Cassava Sciences compare to Voyager Therapeutics?

Do analysts rate VYGR or FLNA?

Does the media refer more to VYGR or FLNA?

Is VYGR or FLNA more profitable?

Which has better earnings and valuation, VYGR or FLNA?

Which has more volatility & risk, VYGR or FLNA?

Do insiders & institutionals believe in VYGR or FLNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools